Androgen deprivation therapy and postprostatectomy radiation: What is the optimal duration?

Documenti analoghi

• Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post‐Randomization Analysis
  di: Sayeh Fattahi, et al.
  Pubblicazione: (2025)
• Insulin resistance during androgen deprivation therapy in men with prostate cancer
  di: Shehzad Basaria, et al.
  Pubblicazione: (2024)
• Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis
  di: Johnathan Zeng, et al.
  Pubblicazione: (2026)
• Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable‐risk prostate cancer patients receiving docetaxel: Insights from a randomized trial
  di: Tyler Walburn, et al.
  Pubblicazione: (2024)
• Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines
  di: Ahmad Mousa, et al.
  Pubblicazione: (2024)